Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Apharm Health Co. Ltd. is currently navigating the patent prosecution landscape within the Biotechnology & Pharmaceuticals technology area. The company's portfolio shows 1 pending office action, which is being handled by 1 distinct examiner. This indicates a specific and singular focus for the firm's current legal efforts at the patent office. The pending matter is located within a distinct art unit, suggesting the technical claims are being evaluated by a specific specialized group. AFREMOVA, VERA is the busiest examiner for the company, currently overseeing the busiest examiner pending office action. As there is only a pending office action in total, this examiner manages all of the company's current pending workload. The concentration of the pending office action within the art unit and under the distinct examiner reflects a streamlined prosecution path for the company's Biotechnology & Pharmaceuticals interests. This structure allows for a direct and focused engagement with the assigned examiner during the review process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AFREMOVA, VERA | 1 | 50.5% | +29.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19202536 | ENZYME FOOD FOR MAINTAINING BODY BALANCE AND PREVENTING METABOLIC SYNDROME THROUGH ENZYMES | AFREMOVA, VERA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19202536 | ENZYME FOOD FOR MAINTAINING BODY BALANCE AND PREVENTING METABOLIC SYNDROME THROUGH ENZYMES | AFREMOVA, VERA | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19202536 | ENZYME FOOD FOR MAINTAINING BODY BALANCE AND PREVENTING METABOLIC SYNDROME THROUGH ENZYMES | AFREMOVA, VERA | 1653 | §101§103§112 | Final Rejection | — | Pending | May 08, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialApharm Health Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Vera Afremova has the most, with 1 of Apharm Health Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
